120 related articles for article (PubMed ID: 10627645)
21. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
22. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
23. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
[TBL] [Abstract][Full Text] [Related]
24. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
[TBL] [Abstract][Full Text] [Related]
25. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
[TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
27. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.
Martino R; Valcárcel D; Brunet S; Sureda A; Sierra J
Bone Marrow Transplant; 2008 Jan; 41(1):33-8. PubMed ID: 17982504
[TBL] [Abstract][Full Text] [Related]
28. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
29. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
30. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
31. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
32. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
33. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
[TBL] [Abstract][Full Text] [Related]
34. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
[TBL] [Abstract][Full Text] [Related]
35. Fluorescence in situ hybridization evaluation of minimal residual disease on stem-cell harvests.
Díez-Martín JL; Buño I; Llamas P; Gosálvez J; López-Fernández C; Polo N; Regidor C
Cancer Detect Prev; 2000; 24(2):169-72. PubMed ID: 10917138
[TBL] [Abstract][Full Text] [Related]
36. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
[TBL] [Abstract][Full Text] [Related]
37. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
38. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
[TBL] [Abstract][Full Text] [Related]
39. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
40. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
Scott BL; Storer B; Loken MR; Storb R; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2005 Jan; 11(1):65-73. PubMed ID: 15625546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
